Michael E. Lindquist

TL;DR: A single non-neutralizing antibody (mAb-13G8) was identified that protected adult type I interferon–deficient mice against lethal infection in a severe disease model and was revealed as GP38, one of multiple proteolytically cleaved glycoproteins derived from the CCHFV glycoprotein precursor polyprotein.

TL;DR: In this study, antibody-mediated blockade of IFN-I signaling in mice was used to study CCHFV liver pathogenesis in various transgenic mouse systems and found that liver injury did not depend on cytotoxic immune cells and observed extensive activation of death receptor signaling pathways in the liver during acute disease.

TL;DR: This study has shown that at non-toxic concentrations Bortezomib, a FDA-approved inhibitor of the proteasome, proved to be a potent inhibitor of VEEV multiplication in the human astrocytoma cell line U87MG and will aid future investigations in identifying host proteins as potential broad spectrum therapeutic targets for treating alphavirus infections.

TL;DR: Recent advances in RNA fluorescence in situ hybridization (FISH) are discussed that not only allow entirely new investigations into the replication of these viruses but also demonstrate how this method can be applied to any virus with a known sequence and how it can be rapidly performed to minimize time spent in high containment.